JP7628962B2 - 乾癬性関節炎に罹患している対象者の治療方法 - Google Patents

乾癬性関節炎に罹患している対象者の治療方法 Download PDF

Info

Publication number
JP7628962B2
JP7628962B2 JP2021561000A JP2021561000A JP7628962B2 JP 7628962 B2 JP7628962 B2 JP 7628962B2 JP 2021561000 A JP2021561000 A JP 2021561000A JP 2021561000 A JP2021561000 A JP 2021561000A JP 7628962 B2 JP7628962 B2 JP 7628962B2
Authority
JP
Japan
Prior art keywords
antibody
week
composition
weeks
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021561000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529266A5 (cg-RX-API-DMAC10.html
JP2022529266A (ja
Inventor
ガノーカー，キルチ・ウォーダマン
ラウト，アトゥール・マチュラダス
ラガヴァン，アニール
ヤオ，シウ－ロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7628962(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2022529266A publication Critical patent/JP2022529266A/ja
Publication of JP2022529266A5 publication Critical patent/JP2022529266A5/ja
Priority to JP2025013906A priority Critical patent/JP2025069284A/ja
Application granted granted Critical
Publication of JP7628962B2 publication Critical patent/JP7628962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021561000A 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法 Active JP7628962B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013906A JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN201921015050 2019-04-15
IN202021004422 2020-01-31
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013906A Division JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Publications (3)

Publication Number Publication Date
JP2022529266A JP2022529266A (ja) 2022-06-20
JP2022529266A5 JP2022529266A5 (cg-RX-API-DMAC10.html) 2023-04-20
JP7628962B2 true JP7628962B2 (ja) 2025-02-12

Family

ID=72837755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561000A Active JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Country Status (16)

Country Link
US (1) US20220298233A1 (cg-RX-API-DMAC10.html)
EP (1) EP3956357A4 (cg-RX-API-DMAC10.html)
JP (2) JP7628962B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210140780A (cg-RX-API-DMAC10.html)
CN (1) CN113825768A (cg-RX-API-DMAC10.html)
AU (1) AU2020259375A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021020612A2 (cg-RX-API-DMAC10.html)
CA (1) CA3143604A1 (cg-RX-API-DMAC10.html)
IL (1) IL287213A (cg-RX-API-DMAC10.html)
JO (1) JOP20210279A1 (cg-RX-API-DMAC10.html)
MA (1) MA55729A (cg-RX-API-DMAC10.html)
MX (1) MX2021012652A (cg-RX-API-DMAC10.html)
MY (1) MY210310A (cg-RX-API-DMAC10.html)
PH (1) PH12021552536A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202111056YA (cg-RX-API-DMAC10.html)
WO (1) WO2020212874A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036280A1 (zh) * 2023-08-11 2025-02-20 信达生物制药(苏州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
TW202511290A (zh) * 2023-09-07 2025-03-16 大陸商信達生物製藥（蘇州）有限公司 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
HUE042172T2 (hu) * 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항－ｉｌ－２３ 항체
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEODHAR, A. et al.，Lancet，2018年，Vol. 391，pp. 2213-2224
MEASE, P.J. et al.，Ann Rheum Dis ，2018年，Vol. 77, Suppl. 2, OP0307欄，doi: https://doi.org/10.1136/annrheumdis-2018-eular.2140

Also Published As

Publication number Publication date
AU2020259375A1 (en) 2021-10-28
MX2021012652A (es) 2022-01-24
EP3956357A4 (en) 2023-01-04
MY210310A (en) 2025-09-10
EP3956357A1 (en) 2022-02-23
SG11202111056YA (en) 2021-11-29
CN113825768A (zh) 2021-12-21
US20220298233A1 (en) 2022-09-22
BR112021020612A2 (pt) 2021-12-28
PH12021552536A1 (en) 2022-07-04
MA55729A (fr) 2022-02-23
JOP20210279A1 (ar) 2021-10-14
WO2020212874A1 (en) 2020-10-22
KR20210140780A (ko) 2021-11-23
JP2022529266A (ja) 2022-06-20
JP2025069284A (ja) 2025-04-30
IL287213A (en) 2021-12-01
CA3143604A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
JP2025069284A (ja) 乾癬性関節炎に罹患している対象者の治療方法
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN112689512B (zh) 用于治疗银屑病的组合物和方法
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
JP2025503948A (ja) 頭皮の尋常性乾癬を有する対象者の治療方法
JP2026062653A (ja) シェーグレン症候群の処置
JP2025534316A (ja) 非活動性又は慢性甲状腺眼症を処置するための方法
AU2023270497A1 (en) Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EA053193B1 (ru) Способы лечения субъектов с псориатическим артритом
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
WO2025146509A1 (en) Methods of treating multifocal motor neuropathy (mmn)
HK40117117A (en) Dosage regimens for treating multifocal motor neuropathy (mmn)
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
US20190247503A1 (en) Methods for treating relapsing forms of multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250130

R150 Certificate of patent or registration of utility model

Ref document number: 7628962

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157